OncoVision In silico tumour growth what-if
Loading data

Illustrative research simulation, not a prediction, not medical advice. Treatment effects in these scenarios are literature priors from randomised trials. In our retrospective data they could not be identified. Scenario effects are literature priors, not measured here. How this was tested

In silico tumour growth · treatment what-if

What would this tumour do if the treatment had been different?

A growth simulation seeded from a real patient's scan segmentations and run forward from the last scan. It runs on one local machine, built so patient data never leaves the device.

measured
from the scans
illustrative
simulated
sample data
bundled sample
AI-written
checked text

Workspace

No patient

Choose a patient

0

Cell-density seed, illustrative. MRI does not measure cell density.

Drag to orbit, scroll to zoom. The cut plane hides one side of the tumour so the inside is visible.

Timeline days since first scan

Day 0

View options: cross-section, opacity, colour scale

Growth curve: tumour burden over time

Patient none selected

Filter and sort

Model parameters

Read-only. These are the values the stored simulation used; this build does not re-run the simulation in the browser.

01Two agents and a rule-based judge

Every sentence carries its receipt

One agent writes the explanation and must cite a verified statement for every sentence. A second agent audits each sentence. A rule-based judge, which is not a language model, checks the numbers and wording and has the last word.

No explanation is stored for this patient.

02Cohort results

What the evidence says

Four results decide how much weight the simulation deserves. They are stated here in full, including the ones that go against the demo.

Treatment effects were not identifiable in our data

not availableversus a no-treatment baseline

Fit result not available in this data file.

measured Details

Mortality risk model

not availablepooled AUC

Risk results not available in this data file.

measured Details

What the scenarios assume

not availablegrowth suppression while an agent is active

Taken from trial progression-free-survival ratios. Not estimated here, and not independent of imaging pseudo-response for bevacizumab.

illustrative Sources

Does the model forecast the next scan?

measured Details

03Intended use, method and limits

Model card

Intended use

Exploring how a treatment assumption changes a growth forecast for a single patient's tumour, and showing what the assumptions are. It is a research demo for a hackathon audience.

Not for choosing or changing treatment, giving a prognosis, or any decision about a person.

What is simulated

A reaction-diffusion model: cells proliferate at rate ρ, spread with diffusion D, and are lost at rate δ. It is seeded from the patient's segmentation masks (core 0.95, enhancing 0.5, oedema 0.2; resection cavity excluded) and run forward from the last scan.

Tumour burden is the sum of density times voxel volume, in cell-equivalent mm³. MRI does not measure cell density, so the density colouring is a modelling choice.

Treatment-effect fit measured

Fit result not available in this data file.

AgentFitted kill rateIntervalIntervals exposed
not available

Priors used in the scenarios illustrative

AgentGrowth suppression while activeSource
Loading

The temozolomide median PFS figure (6.9 vs 5.0 months) was not independently verified; the overall-survival hazard ratio of 0.63 was. Radiation uses a placeholder, not a measured effect.

Mortality risk model measured

This is a separate model from the growth simulation. It ranks patients by mortality risk and does not predict tumour growth.

Risk results not available in this data file.

Forecast check measured

Loading

MethodTypical error (log ratio)Typical factor offDirection right

Limits to keep in mind

  • Scenario curves are what the model does under assumed effects. They are not what would have happened to this patient.
  • Growth rate ρ is calibrated on a single interval per patient. Some fits do not converge; those are flagged and should not be read.
  • Density is a seed built from segmentation labels, not a measurement. The 3D view is a 32×32×32 display grid, so fine structure is lost.
  • Treatment records come from clinical sheets; where an end date was missing it was assumed, and the assumption is listed per patient.
  • Missing values are shown as "not available". They are never replaced by zero.

Evidence & methodology

What is simulated

A reaction-diffusion model: cells proliferate at rate ρ, spread with diffusion D, and are lost at rate δ. It is seeded from the patient's segmentation masks (core 0.95, enhancing 0.5, oedema 0.2; resection cavity excluded) and run forward from the last scan.

Tumour burden is the sum of density times voxel volume, in cell-equivalent mm³. MRI does not measure cell density, so the density colouring is a modelling choice.

Where the scenario effects come from illustrative

Treatment effects are not estimated from this cohort. Scenario effects are literature priors, so every scenario curve is illustrative.

What it is not

Not for choosing or changing treatment, giving a prognosis, or any decision about a person. It is a research demo.

What the evidence says · Full model card · How the explanation was checked